Compare Gilead Sciences, Inc. (GILD) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Ralph Lauren Corp — how do they compare? Gilead Sciences, Inc. trades at $135.36 (market cap $163.51B), while Ralph Lauren Corp trades at $373.86 (market cap $22.26B). The key difference: Gilead Sciences, Inc. is far larger — about 7.3× Ralph Lauren Corp's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | RL | |
|---|---|---|
Market Cap | $163.51B | $22.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $414.25 |
52-Week Low | $108.22 | $283.34 |
Enterprise Value | $178.05B | $23.21B |
Dividend Yield | 2.49% | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Ralph Lauren (RL) trades at $385.13, up 4.38% over the past day, with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from robust fundamentals including 69.87% gross margins and 34.66% ROE. Revenue growth accelerated to $7.08 billion in 2025, with net income reaching $743 million. Analyst sentiment remains positive with a $445.71 consensus price target, though technical indicators suggest near-term resistance at $386.
The outlook for RL is favorable given consistent earnings outperformance and brand strength in key markets like Asia. Risks include premium valuation multiples and macroeconomic pressures on consumer spending. Wall Street maintains a bullish stance with 66% of analysts rating it a Buy, projecting 16% upside from current levels based on continued digital and direct-to-consumer expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
